yxgaxjlywf
helikopter
Dołączył: 03 Mar 2011
Posty: 735
Przeczytał: 0 tematów
Ostrzeżeń: 0/10
Skąd: England
|
 Wysłany: Wto 10:21, 15 Mar 2011 Temat postu: mbt scarpe ekk fhm nje irk |
|
|
Primary brain stem hemorrhage in 30 cases
008.03.13 Revised) (This edit Li Guoqi) of recombinant human brain natriuretic peptide in acute pulmonary embolism caused by the effect of pulmonary hypertension, animal husbandry, Liang Haiqing Song Yuzhang Yun Wang Guo Qiang Cai Hongbin Wang Xiaomei Keywords Xiongguan natriuretic peptide, brain pulmonary hypertension , Gene therapy of acute pulmonary embolism (pulmonarythromboembolism, PTE) refers to the systemic venous system of free emboli within the pulmonary trunk or its branches after the blockage of pulmonary circulation disorders caused by the clinical and pathophysiological syndrome, is a clinical high morbidity, high death rate and high rate of misdiagnosis of common diseases. Despite the rapid thrombolysis and anticoagulation therapy can improve clinical symptoms, but acute pulmonary high ~, (pulmonaryarteryhy.pertension, PAH) in the treatment of limited means. Recombinant human brain natriuretic peptide (rhBNP) used in the clinical treatment of pulmonary hypertension are more satisfied with the results obtained 【】】. I m in 9 cases of acute pulmonary hypertension in patients with intravenous recombinant human brain natriuretic peptide, to observe the effect. 1 object object of study and methods 1.1 September 2003 一 May 2007 Tianjin TEDA International Cardiovascular Hospital CCU 16 patients hospitalized patients with pulmonary embolism, 7 males and 9 females, aged 54-88 years (mean 72 .25 ± 11.36) years. All patients were ventilated by radionuclide lung perfusion scanning, cT pulmonary angiography (CTPA) and magnetic resonance pulmonary angiography (MRPA) and other three kinds of diagnosis methods 1 or 2 were diagnosed as pulmonary embolism, in line with respiratory disease branch of the Chinese Medical Association the development of pulmonary embolism diagnosis and treatment guidelines standards f1]. Exclusion criteria: specific chronic thromboembolic pulmonary hypertension and with no recent new m persons with acute, active internal bleeding or intracranial hemorrhage,[link widoczny dla zalogowanych], cardiopulmonary resuscitation,[link widoczny dla zalogowanych], those patients, the platelet count below 100 × 109 / L are difficult to control with severe hypertension (systolic blood pressure> 180mmHg or diastolic blood pressure> 110mmHg), severe liver 'kidney dysfunction, diabetes, hemorrhagic retinopathy and pregnancy. Were randomly divided into 2 groups: treatment group 9 cases, 5 males and 4 females, mean age (66.33-4-10.39) years; control group, 7 patients, 4 males and 3 females, mean age ( 68.00 ± 8.25) years of age, 2 groups of ~ JIJ (p = O.949), the age (t = O.347) the difference was not statistically significant (P> O.05). Research Methods 1.2 treatment group, rhBNP (new bios, Tibet Nuodikang Biological Pharmaceutical Co., Ltd.) dose: 90s uniform intravenous bolus 1.5g/ks, O. 0075Ixg / (kg · min) intravenous infusion to maintain 3h, the systolic blood pressure (SBP)> 85mm №, mean pressure> 65mmHg in the state,[link widoczny dla zalogowanych], adjust the dose of O. A O. 015 030 (ks · min), intravenous infusion of 48h, the routine use of urokinase in 15 × 1o5-2O × 1o5U dissolved in 100mL of normal saline, 2h the intravenous drip; then given low molecular weight heparin 5000U, each 12h1 times subcutaneously Used 5-7d, 4 days plus service in the warfarin 23mrCd. Control group, routine use of thrombolysis and anticoagulation only treatment. Were recorded before treatment, 30min and 24h after intravenous injection in patients with respiratory v, heart rate, f} IR], central venous pressure (cvP), pulmonary artery pressure (PAP), alveolar arterial oxygen pressure [AaDp (0, partial pressure of oxygen 【P (0) and carbon dioxide partial pressure】 【P (CO)】. 1.3 statistical package SPSS13.0 Statistical Methods, repeated measurements of each parameter analysis of variance. 2 results of 2 groups after treatment indicators are gradually improving, treatment group than in the control group to improve the situation earlier and better improvement than the control group, Table 1,2. 3 Discussion of pulmonary hypertension is still a lack of effective treatment, symptomatic treatment of first choice vasodilators, nitroglycerin and sodium nitroprusside commonly used clinical However, as non-selective vasodilator, the effect is poor. more effective the treatment of pulmonary hypertension is epoprostenol drugs, the short-term effect of good, can improve hemodynamic parameters of pulmonary circulation and improve the 2-year survival; but not anti-right ventricular hypertrophy proliferative effect, long-term survival poor,[link widoczny dla zalogowanych], and expensive,[link widoczny dla zalogowanych], domestic unlisted. brain natriuretic peptide (BNP) in 1988 first discovered in porcine brain, the main loop from the heart. BNP is the heart of a major unit : 300457 Tianjin TEDA International Cardiovascular Hospital CCU
Post został pochwalony 0 razy
|
|
